ESMO Program

Top

MD Anderson Presentations at ESMO

MD Anderson has numerous presentations throughout the ESMO program. Note: All times are listed in CEST (Central European Summer Time).

Friday, October 17

16:00�C17:30 (4�C5:30 p.m.)
Berlin Auditorium, Hub 27

LBA72: NorthStar: A Phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter:

LBA75: Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study
Presenter:

16:00�C17:30 (4�C5:30 p.m.)
Heidelberg Auditorium, Hall 6.2

Abstract 924MO: First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors
Presenter:

Saturday, October 18

08:30�C9:45
Heidelberg Auditorium, Hall 6.2

Talk: Emerging medical therapies for brain and leptomeningeal melanoma metastases
Presenter and Session Chair:

08:30�C10:00
Dortmund Auditorium, Hall 7.1a

Talk: Clinical advances in targeting chromosomal instability
Presenter:

08:30�C10:00
Berlin Auditorium, Hub 27

LBA94: LenCabo: A randomized Phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)
Presenter:

08:30�C10:00
Hanover Auditorium, Hall 7.2c

Talk: Can we improve drug development in colorectal cancer? Turning failure into success
Presenter:

08:30�C10:00
Cologne Auditorium, CityCube A

Abstract 113MO: Multimodal molecular investigation of >1,000 rare cancer patients (pts) reveals key tumor states and germline susceptibility genetics
Presenter:

08:45�C9:30
Bremen Auditorium, Hall 6.2

Presenter:

10:15�C11:45
Karlsruhe Auditorium, Hall 5.2

Abstract 1705O: LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma
Presenter:

Sunday, October 19

08:30�C10:00
Solingen Auditorium, Hall 23

Abstract 1250MO: Outcomes of patients with chronic myeloid leukemia receiving second-line therapy
Presenter:

08:30�C10:00
Nuremberg Auditorium, Hall 5.2

Talk: ADC and PARP/DDR inhibitor combinations
Presenter:

10:15�C11:30
Bremen Auditorium, Hall 6.2

Talk: RT for angiosarcoma: Sequencing therapies
Presenter and Session Chair:

14:45�C16:15 (2:45�C4:15 p.m.)
Hanover Auditorium, Hall 7.2c

Talk: Resectable NSCLC without oncogene addiction
Presenter and Session Chair:

14:45�C16:00 (2:45�C4 p.m.)
Hanover Auditorium, Hall 7.2c

LBA54: SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade
Presenter: Adam Grippin, M.D., Ph.D.

14:45�C16:15 (2:45�C4:15 p.m.)
Cologne Auditorium, CityCube A

Abstract 737MO: Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): final analysis of DESTINY-CRC02, a randomized, Phase II trial
Presenter:

14:45�C16:15 (2:45�C4:15 p.m.)
Bremen Auditorium, Hall 6.2

Chair:

16:30�C18:00 (4:30�C6 p.m.)
Cologne Auditorium, CityCube A

Abstract 1326MO: RTOG 1016 long-term update and smoking analysis
Presenter:

16:30�C18:00 (4:30�C6 p.m.)
Hanover Auditorium, Hall 7.2c

Abstract 920O: Safety and efficacy of first-in-class, YAP/TEAD inhibitor, VT3989 in refractory pleural and non-pleural mesothelioma: A Phase I/II study
Presenter:

Monday, October 20

08:30�C10:00
Hanover Auditorium, Hall 7.2c

Talk: Aggressive variant prostate cancer
Presenter and Session Chair:

08:30�C10:00
Bonn Auditorium, Hall 7.1c

Abstract 81MO: Survival and Safety of Tinengotinib in Pooled Patients with Advanced, Fibroblast Growth Factor Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma (CCA)
Presenter:

08:30�C10:00
Berlin Auditorium, Hub 27

Abstract 729O: Circulating tumor (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER
Presenter:

10:15�C11:45
Bonn Auditorium, Hall 7.1c

Talk: TCR mimic bispecifics?
Presenter and Session Chair: Timothy Heffernan, Ph.D.

14:45�C16:15 (2:45�C4:15 p.m.)
Hamburg Auditorium, CityCube A

LBA70: Association of radiomic features �� on-treatment ctDNA detection with treatment outcomes in patients with resectable NSCLC: exploratory analyses from AEGEAN
Presenter:

16:30�C18:00 (4:30�C6 p.m.)
Nuremberg Auditorium, Hall 5.2

Talk: Rediscovering CTLA-4 blockade
Presenter:

Posters

Posters are displayed in Hall 25 on a rotating schedule. Presenters will be at their posters from 12:00 to 12:45 on their assigned presentation day.

Saturday, Oct. 18

Gynaecological cancers

1112P: Phase II randomized controlled trial of everolimus and letrozole with or without ribociclib in advanced/recurrent endometrial cancer (EC)
Presenter:

1117P: Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial
Presenter:

Haemtaological malignancies

1284P: CDK9 inhibition enhances venetoclax activity and prolongs survival in a T-PLL patient-derived xenograft model
Presenter: Claudia Kettlun Leyton, Ph.D.

Prostate cancer

2467P: Higher circulating tumor DNA levels in chemo-experienced mCRPC patients serve as a poor prognostic marker for checkpoint inhibitors (CI) or chemotherapy: A post hoc analysis of CM 650
Presenter:

2518TiP: Presurgical Phase II study of talazoparib in combination with enzalutamide in de novo metastatic to lymph nodes prostate cancer (TEN+)
Presenter:

NSCLC, metastatic

2020P: Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study
Presenter:

Renal cancer

2631P: Unmet needs & disparities in kidney cancer (KC): International Kidney Cancer Coalition (IKCC) global patient survey (GPS)
Presenter:

SCLC

2785P: Real-world treatment patterns and progression-free survival from first-line chemoimmunotherapy in patients with extensive-stage small cell lung cancer in the US
Presenter:

Urothelial cancer

3094P: Validation of prognostic scores for advanced urothelial cancer (aUC) for enfortumab vedotin/pembrolizumab (EVP): Analysis of the UNITE study
Presenter: Cindy Jiang, M.D.

Sunday, Oct. 19

Biliary tract cancer, incl. cholangiocarcinoma

81P: Survival and safety of tinengotinib in pooled patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma (CCA)
Presenter:

94P: The association between tumor immunogenomic features and first line (1L) therapeutic outcomes in advanced biliary tract cancer (BTC)
Presenter:

Colorectal cancer

737P: Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): final analysis of DESTINY-CRC02, a randomized, Phase II trial
Presenter:

743P: Combined analysis of overall survival (OS) from the Phase III CodeBreaK 300 and phase 1b CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)
Presenter:

799P: Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a Phase Ib/II study
Presenter:

809P: Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) �� mFOLFOX6 and chemotherapy (chemo) �� bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER)
Presenter:

893eP: Boarding time as a predictor of short-term mortality in colorectal cancer patients visiting the emergency department
Presenter: Denise Langabeer

909eTiP: Open-label Phase II trial of AMB-05X for patients with ctDNA(+) colorectal cancer after curative-intent treatment
Presenter: Michael LaPelusa, M.D.

Developmental Therapeutics

939P: Phase I, dose-escalation study evaluating safety & efficacy of trastuzumab deruxtecan (T-DXd) in combination with ATR inhibitor (AZD6738, ceralasertib) in advanced solid tumors with HER2 expression (DASH)
Presenter:

962P: Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer: Updated clinical data from the Phase I PROCEADE-CRC-01 study
Presenter:

971P: Efficacy and safety of larotrectinib in patients with TRK fusion cancer who had a long-term response
Presenter:

977P: DS3201, an EZH1/2 inhibitor, with ipilimumab in patients with refractory genitourinary tumors
Presenter:

983P: Phase I/II clinical study of a first-in-class antisense oligonucleotide (TTX-MC138) therapeutic against advanced solid tumors of multiple tissue origins
Presenter:

986P: Phase I study of NovoTTF-100L(P) in combination with chemotherapy in patients with predominant hepatic metastatic colorectal cancer
Presenter:

987P: Phase i study of tumor treating fields (TTFS) with cabozantinib or with nab-paclitaxel and pembrolizumab in patients with advanced solid tumors involving the abdomen or thorax
Presenter:

990P: Concordance analysis of DNA and RNA profiling: Results of the MD Anderson IMPACT2 study in precision oncology
Presenter: Stephanie Schmidt, Ph.D.

Investigational immunotherapy

1526P: Unexpected improvements in survival among patients treated with immune checkpoint inhibitors during the COVID-19 pandemic are strongly associated with SARS-CoV-2 mRNA vaccination
Presenter: Adam Grippin, M.D., Ph.D.

1564P: First-in-human, Phase I study of BGB-26808 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) �� tislelizumab (TIS; anti-PD-1) in advanced solid tumors (STs)
Presenter:

Pancreatic cancer

2248P: Integrated analysis of KRAS mutations and MTAP loss in pancreatic cancer reveals potential for combined blockade of KRAS and PRMT5
Presenter:

Monday, Oct. 20

Biomarkers & translational research (agnostic)

120P: Dynamic evolution of precision oncology decision support for clinical care
Presenter: Amber Johnson, Ph.D.

123P: Cancer signal origin (CSO) prediction in cancer of unknown primary (CUP) syndrome (CRONUS) using circulating tumor DNA (ctDNA)
Presenter:

Breast cancer, early stage

303P: Biosimilar tastuzumab (T) and cardiotoxicity in patients with early-stage breast cancer (BC)
Presenter:

413P: Decision regret in older breast cancer survivors
Presenter:

Breast cancer, metastatic

520P: Long-term safety and efficacy of first-line atirmociclib + letrozole for the treatment of patients with HR+/HER2? metastatic breast cancer (mBC)
Presenter:

567P: Accumulation of CD38 in hybrid epithelial/mesenchymal cells promotes immune remodeling and metastasis in breast cancer
Presenter: Tanvi Visal

605P: Outcomes of subsequent antibody drug conjugate (ADC) regimen in ADC-resistant HER2 low metastatic breast cancer
Presenter:

CNS tumors

712TiP: Concurrent intrathecal (IT) and intravenous (IV) nivolumab (nivo) and relatlimab (rela) for melanoma patients (pts) with leptomeningeal disease (LMD)
Presenter:

Head and neck, excluding thyroid

1350P: Immuno-chemotherapy alone for laryngeal cancer: ICoLP Phase II Trial with >2-year follow-up
Presenter:

1407P: Using liquid biopsies to classify adenoid cystic carcinoma into clinically relevant subtypes
Presenter: Simon Heeke, Ph.D.

Melanoma and other skin tumors

1612P: Characterization of tumor and peripheral biomarkers in patients (pts) with resectable melanoma (MEL) treated with adjuvant nivolumab + relatlimab (NIVO + RELA) or NIVO alone in RELATIVITY-098
Presenter:

1619P: Pooled outcomes with first-line nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma (MEL)
Presenter:

1659P: Updated pathologic responses from a pilot Phase II Trial of neoadjuvant immunotherapy for stage ii-iv resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
Presenter:

1701eTiP: NRG-HN014 (C-PRE): A randomized phase 3 study of neoadjuvant immunotherapy with response-adapted treatment versus standard-of-care treatment for patients with resectable stage III-IV (M0) cutaneous squamous cell carcinoma (cSCC)
Presenter:

Sarcoma

2750eP: Molecular tumor boards (MTB) as a tool for Phase I and II clinical trial (CT) selection in sarcoma: A 5-Year retrospective study
Presenter: Carlos Torrado Martin, M.D.

�鶹ӳ��